Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Trial details
- Registry ID
- NCT06173531
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as ACP-101
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromeNCT06173531 | ACAD | Phase 3 | Completed | 2025-08-19Actual |
| OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromeNCT06420297 | ACAD | Phase 3 | Terminated | 2025-12-19Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |